OR WAIT null SECS
The 110,000 ft2 site, which is set to be operational by the second half of 2021, will feature new technology including 2000-L scale bioreactors and additional fill-finish capabilities.
Vibalogics, a Germany-based contract development and manufacturing organization (CDMO), announced on Nov. 16, 2020 that it has begun its three-year, $150 million investment into a late-phase clinical and commercial virotherapy manufacturing facility near Boston, MA, thus establishing its presence in the United States.
The 110,000 ft2 site, which is set to be operational by the second half of 2021, will feature new technology including 2000-L scale bioreactors and additional fill/finish capabilities, a company press release said.
“We are very excited about our choice of facility, as it meets both our current and future needs, giving us the ability to expand further to meet growing customer demand,” said Tom Hochuli, Vibalogics’ CEO, in the press release. “The site will provide a complete suite of virotherapy services to support drug developers and their most revolutionary products. The addition of a late stage clinical and commercial facility means we can easily tech transfer our customers’ products from our early phase manufacturing facility in Germany to the US, resulting in a complete end-to-end service from pre-clinical to commercial supply.”